novocure ltd - NVCR
NVCR
Close Chg Chg %
13.27 0.17 1.28%
Closed Market
13.44
+0.17 (1.28%)
Volume: 401.45K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: novocure ltd - NVCR
NVCR Key Data
| Open $13.27 | Day Range 13.23 - 13.53 |
| 52 Week Range 10.70 - 32.06 | Market Cap $1.49B |
| Shares Outstanding 111.98M | Public Float 100.42M |
| Beta 0.82 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.61 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.78M |
NVCR Performance
| 1 Week | 4.67% | ||
| 1 Month | 4.92% | ||
| 3 Months | 4.27% | ||
| 1 Year | -56.22% | ||
| 5 Years | -92.18% |
NVCR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About novocure ltd - NVCR
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
NVCR At a Glance
NovoCure Ltd.
No. 4 The Forum
St. Helier, Jersey JE2 4UF
| Phone | 44-15-3475-6700 | Revenue | 605.22M | |
| Industry | Medical Specialties | Net Income | -168,627,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 18.825% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,488 | |
| View SEC Filings |
NVCR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.31 |
| Price to Book Ratio | 8.978 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -18.775 |
| Enterprise Value to Sales | 4.849 |
| Total Debt to Enterprise Value | 0.233 |
NVCR Efficiency
| Revenue/Employee | 406,733.871 |
| Income Per Employee | -113,324.597 |
| Receivables Turnover | 6.136 |
| Total Asset Turnover | 0.507 |
NVCR Liquidity
| Current Ratio | 1.463 |
| Quick Ratio | 1.417 |
| Cash Ratio | 1.272 |
NVCR Profitability
| Gross Margin | 77.50 |
| Operating Margin | -27.682 |
| Pretax Margin | -21.672 |
| Net Margin | -27.862 |
| Return on Assets | -14.129 |
| Return on Equity | -46.667 |
| Return on Total Capital | -16.159 |
| Return on Invested Capital | -23.483 |
NVCR Capital Structure
| Total Debt to Total Equity | 189.722 |
| Total Debt to Total Capital | 65.484 |
| Total Debt to Total Assets | 55.073 |
| Long-Term Debt to Equity | 32.559 |
| Long-Term Debt to Total Capital | 11.238 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Novocure Ltd - NVCR
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 535.03M | 537.84M | 509.34M | 605.22M | |
Sales Growth
| +8.23% | +0.53% | -5.30% | +18.82% | |
Cost of Goods Sold (COGS) incl D&A
| 114.24M | 114.26M | 127.53M | 136.18M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.25M | 10.62M | 10.97M | 11.23M | |
Depreciation
| 10.25M | 10.62M | 10.97M | 11.23M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +7.68% | +0.02% | +11.62% | +6.77% | |
Gross Income
| 420.79M | 423.58M | 381.80M | 469.05M | |
Gross Income Growth
| +8.38% | +0.66% | -9.86% | +22.85% | |
Gross Profit Margin
| +78.65% | +78.76% | +74.96% | +77.50% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 464.49M | 512.50M | 607.96M | 636.58M | |
Research & Development
| 201.30M | 206.09M | 220.99M | 209.37M | |
Other SG&A
| 263.18M | 306.41M | 386.97M | 427.21M | |
SGA Growth
| +29.94% | +10.34% | +18.63% | +4.71% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 639.00K | 611.00K | 6.71M | 2.96M | |
EBIT after Unusual Expense
| (44.33M) | (89.52M) | (232.87M) | (170.50M) | |
Non Operating Income/Expense
| 1.10M | 15.79M | 46.04M | 51.00M | |
Non-Operating Interest Income
| 1.10M | 15.79M | 46.04M | 51.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 8.84M | 8.11M | 4.91M | 11.66M | |
Interest Expense Growth
| -51.03% | -8.21% | -39.53% | +137.73% | |
Gross Interest Expense
| 8.84M | 8.11M | 4.91M | 11.66M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (52.08M) | (81.85M) | (191.74M) | (131.16M) | |
Pretax Income Growth
| -387.68% | -57.17% | -134.27% | +31.59% | |
Pretax Margin
| -9.73% | -15.22% | -37.64% | -21.67% | |
Income Tax
| 6.28M | 10.69M | 15.30M | 37.47M | |
Income Tax - Current - Domestic
| 65.00K | 469.00K | 2.16M | 3.86M | |
Income Tax - Current - Foreign
| 6.21M | 10.22M | 13.14M | 33.60M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (58.35M) | (92.53M) | (207.04M) | (168.63M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (58.35M) | (92.53M) | (207.04M) | (168.63M) | |
Net Income Growth
| -394.58% | -58.58% | -123.75% | +18.55% | |
Net Margin Growth
| -10.91% | -17.20% | -40.65% | -27.86% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (58.35M) | (92.53M) | (207.04M) | (168.63M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (58.35M) | (92.53M) | (207.04M) | (168.63M) | |
EPS (Basic)
| -0.5641 | -0.8841 | -1.946 | -1.5638 | |
EPS (Basic) Growth
| -387.51% | -56.73% | -120.11% | +19.64% | |
Basic Shares Outstanding
| 103.43M | 104.66M | 106.39M | 107.83M | |
EPS (Diluted)
| -0.5641 | -0.8841 | -1.946 | -1.5638 | |
EPS (Diluted) Growth
| -410.12% | -56.73% | -120.11% | +19.64% | |
Diluted Shares Outstanding
| 103.43M | 104.66M | 106.39M | 107.83M | |
EBITDA
| (33.44M) | (78.29M) | (215.19M) | (156.30M) | |
EBITDA Growth
| -183.69% | -134.09% | -174.87% | +27.36% | |
EBITDA Margin
| -6.25% | -14.56% | -42.25% | -25.83% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 24.929 | |
| Number of Ratings | 7 | Current Quarters Estimate | -0.402 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -1.403 | |
| Last Quarter’s Earnings | -0.33 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.56 | Next Fiscal Year Estimate | -1.494 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 5 | 8 | 8 |
| Mean Estimate | -0.40 | -0.37 | -1.40 | -1.49 |
| High Estimates | -0.31 | -0.32 | -1.31 | -1.19 |
| Low Estimate | -0.50 | -0.42 | -1.54 | -1.91 |
| Coefficient of Variance | -16.64 | -11.85 | -6.05 | -15.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Novocure Ltd - NVCR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Novocure Ltd - NVCR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 7, 2025 | Frank Leonard EVP, Pres., Novocure Oncology | 198,648 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 3,613,407.12 |
| Mar 7, 2025 | Frank Leonard EVP, Pres., Novocure Oncology | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Ashley Cordova Chief Executive Officer | 355,186 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 6,460,833.34 |
| Mar 7, 2025 | Ashley Cordova Chief Executive Officer | 224,123 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Nicolas Leupin Chief Medical Officer | 105,108 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 1,911,914.52 |
| Mar 7, 2025 | Nicolas Leupin Chief Medical Officer | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Christoph Brackmann Chief Financial Officer | 121,150 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 2,203,718.50 |
| Mar 7, 2025 | Christoph Brackmann Chief Financial Officer | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Uri Weinberg Chief Innovation Officer | 221,218 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 4,023,955.42 |
| Mar 7, 2025 | Uri Weinberg Chief Innovation Officer | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Barak Ben Arye General Counsel | 173,696 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 3,159,530.24 |
| Mar 7, 2025 | Barak Ben Arye General Counsel | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michal Nath Puri Chief Human Resources Officer | 163,681 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 2,977,357.39 |
| Mar 7, 2025 | Michal Nath Puri Chief Human Resources Officer | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Mukund Paravasthu Chief Operating Officer | 84,148 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $18.19 per share | 1,530,652.12 |
| Mar 7, 2025 | Mukund Paravasthu Chief Operating Officer | 81,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |